grant
Induction of strong and durable cellular and humoral immunity against HIV using DNA-LNPs
NIHUS FederalResearch GrantFY2026AIDS VaccinesAIDS VirusAIDS vaccineAIDS/HIVAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAnimalsAntibody ResponseAntigensAutologousBinding SitesBlood SerumCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCell Mediated ImmunologyCell-Mediated ImmunityCellular ImmunityCombining SiteDNADNA deliveryDataDeoxyribonucleic AcidDevelopmentDoseEnv trimerGoalsHIVHIV EnvHIV envelopeHIV envelope proteinHIV glycoprotein EnvHIV vaccinatedHIV vaccinationHIV vaccineHIV-1 EnvHIV-1 envelopeHIV-1 glycoprotein EnvHIV-1 vaccinationHIV-1 vaccineHIV/AIDSHIV/AIDS VaccinesHIV1 vaccineHumanHuman Immunodeficiency VirusesHumoral ImmunitiesImmuneImmunesKineticsLAV-HTLV-IIILymphadenopathy-Associated VirusM mulattaM tuberculosis infectionM. mulattaM. tb infectionM. tuberculosis infectionM.tb infectionM.tuberculosis infectionMTB infectionMacaca mulattaMacaca rhesusMembraneMessenger RNAMethodsMiceMice MammalsModelingModern ManMurineMusMycobacterium tuberculosis (MTB) infectionMycobacterium tuberculosis infectionRNA vaccineRNA-based vaccineReactive SiteRegimenRhesus MacaqueRhesus MonkeySHIVSHIV vaccineSIVSOSIPSerumSimian Immunodeficiency VirusesT cell responseT-CellsT-LymphocyteT8 CellsT8 LymphocytesTB infectionTechnologyTestingToxic effectToxicitiesTuberculosisVaccinationVaccinesVaginaVirus ReplicationVirus-HIVVirus-like particleantibody-based immunitycostcross reactivitydeliver DNAdetermine efficacydevelop a vaccinedevelop vaccinesdevelopment of a vaccinedevelopmentaldisseminated TBdisseminated tuberculosisefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy testingevaluate efficacyexamine efficacygp160human immunodeficiency virus vaccineimmunization strategyimmunogenimmunogenicityimprovedinfection due to Mycobacterium tuberculosislipid based nanoparticlelipid nanoparticlemRNAmRNA lipid nano particle vaccinemRNA vaccinemRNA-LNP based vaccinemRNA-LNP combination vaccinesmRNA-LNP vaccinesmRNA-based vaccinemanufacturemembrane structurenano particle deliverynanoparticle deliverednanoparticle deliveryneutralizing antibodynon vaccinatednon-human primatenonhuman primatenot vaccinatednovelnucleic acid deliveryresident memory T cellresponsesimian HIVsimian HIV vaccinesimian human immunodeficiency virussimian human immunodeficiency virus vaccinethymus derived lymphocytetissue resident memory T celltuberculosis infectiontuberculous spondyloarthropathyunvaccinatedvaccination against HIVvaccination against HIV-1vaccination strategyvaccination with HIVvaccine against HIVvaccine against HIV-1vaccine developmentvaccine efficacyviral multiplicationviral replicationvirus multiplicationvirus-like nanoparticlesviruslike particle
Description preview
The overall goal of this proposal is to develop a vaccination strategy that induces strong and durable humoral
and cellular immunity against HIV, providing long-term protection even with low neutralizing antibody (Ab)
responses using DNA-LNP technology. Developing an effective HIV-1 vaccine has been an elusive goal for over
four decades. An ideal…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click